v3.26.1
Debt
12 Months Ended
Dec. 31, 2025
Debt Disclosure [Abstract]  
Debt

Note 6 – Debt

 

The following represents a summary of the Company’s notes payable – SBA government, notes payable – related parties, convertible notes payable and notes payable, key terms, and outstanding balances at December 31, 2025 and 2024, respectively:

 

Notes Payable – SBA government

 

Economic Injury Disaster Loan (“EIDL”)

 

During 2020, this program was made available to eligible borrowers in light of the impact of the COVID-19 pandemic and the negative economic impact on the Company’s business. Proceeds from the EIDL were used for working capital purposes.

 

 

SURGEPAYS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2025 AND 2024

 

Installment payments, including principal and interest, are due monthly (beginning twelve (12) months from the date of the promissory note) in amounts ranging from $74 - $731/month. The balance of principal and interest is payable over the next thirty (30) years from the date of the promissory note. There are no penalties for prepayment. The EIDL Loan was not required to be refinanced by the PPP loan.

 

   EIDL   EIDL     
Terms  SBA   SBA   Total 
             
Issuance dates of SBA loans   May 2020    July 2020      
Term   30 Years    30 Years      
Maturity date   May 2050    July 2050      
Interest rate   3.75%   3.75%     
Collateral   Unsecured    Unsecured      
                
Balance - December 31, 2023   141,994    318,529    460,523 
Interest expense adjustment - SBA loans   5,487    14,263    19,750 
Repayments   (3,532)   (7,345)   (10,877)
Balance - December 31, 2024   143,949    325,447    469,396 
Repayments   (3,430)   (7,632)   (11,062)
Balance - December 31, 2025  $140,519   $317,815   $458,334 

 

Note Payable – Related Party

 

The following is a summary of the Company’s Note Payable - Related Party:

 

   1   1   Total 
Balance - December 31, 2023   -    4,584,563    4,584,563 
Reclassification of principal into one single note   4,584,563    (4,584,563)   - 
Reclassification of accrued interest payable into one single note   498,991    -    498,991 
Repayments   (1,527,899)   -    (1,527,899)
Balance - December 31, 2024   3,555,655    -    3,555,655 
Repayments   (824,859)   -    (824,859)
Balance - December 31, 2025  $2,730,796   $-   $2,730,796 

 

1Activity is with the Company’s Chief Executive Officer and Board Member (Kevin Brian Cox).

 

On March 12, 2024, as approved by the Audit Committee, the Company consolidated all remaining outstanding principal and accrued interest of $4,584,563 and $498,991, respectively, into a single consolidated note with an aggregate face amount of $5,083,554. The consolidated note bears interest at 10% per annum, with a default interest rate of 15%, and is repayable in equal monthly installments of $164,039 over 36 months, resulting in total aggregate payments of $5,905,427 inclusive of interest. The note is unsecured and was scheduled to be repaid in full by December 2026.

 

 

SURGEPAYS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2025 AND 2024

 

Beginning in July 2025, monthly payments under the consolidated note were temporarily suspended as a result of the Company’s current cash flow constraints. The note holder has confirmed that the suspension does not constitute a default under the note terms; accordingly, the 15% default interest rate has not been triggered, and interest has continued to accrue at the contractual rate of 10% per annum. The suspension did not result in a modification of the note’s contractual terms and does not constitute a troubled debt restructuring. Management is evaluating options to restructure or resume payments in future periods.

 

See Note 12 for information regarding the conversion of $1,000,000 of note principal into shares of common stock.

 

The following is a detail of the Company’s Notes Payable - Related Party:

 

Note Payable - Related Party
Note Holder  Issue Date  Maturity Date  Interest Rate   Default Interest Rate   Collateral  December 31, 2025   December 31, 2024 
Note #1  December 31, 2023  December 31, 2026   10.00%   15.00%  Unsecured  $2,730,796   $3,555,655 
                   Short Term   2,730,796    1,689,367 
                   Long Term  $-   $1,866,288 

 

Convertible Notes Payable

 

The following is a summary of the Company’s Convertible Notes Payable and related Debt Discounts:

 

   Note #1   Note #2   Note #3   Note #4   Note #5   Note #6   Total 
Balance - December 31, 2024  $-   $-   $-   $-   $-   $-   $- 
Face amount of note   6,000,000    770,000    660,000    385,000    385,000    495,000    8,695,000 
Stated guaranteed earned interest added to note   -    61,600    52,800    30,800    30,800    39,600    215,600 
Increase in note balance - common stock repurchase ($3/share)   999,999    -    -    -    -    -    999,999 
Debt discount   (1,679,927)   (224,900)   (182,720)   (106,780)   (104,580)   (126,500)   (2,425,407)
Amortization of debt discount   559,976    74,967    45,680    26,695    26,145    21,083    754,546 
Balance - December 31, 2025  $5,880,048   $681,667   $575,760   $335,715   $337,365   $429,183   $8,239,738 
                                    
Unamortized debt discount  $1,119,951   $149,933   $137,040   $80,085   $78,435   $105,417   $1,670,861 

 

Debt Discount Components                     
Debt Discount Components  Note #1   Note #2   Note #3   Note #4   Note #5   Note #6   Total 
Warrants  $1,084,927   $-   $-   $-   $-   $-   $1,084,927 
Legal fees   175,000    7,500    2,000    1,500    -    2,000    188,000 
Broker fee   420,000    -    -    -    -    -    420,000 
Discount - Original Issue Discount   -    70,000    60,000    35,000    35,000    45,000    245,000 
Discount - Stated Guaranteed Interest   -    61,600    52,800    30,800    30,800    39,600    215,600 
Discount - Commitment Shares (common stock)   -    85,800    67,920    39,480    38,780    39,900    271,880 
Total debt discounts  $1,679,927   $224,900   $182,720   $106,780   $104,580   $126,500   $2,425,407 

 

 

SURGEPAYS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2025 AND 2024

 

The following is a detail of the Company’s Convertible Notes Payable:

 

Convertible Notes Payable - Net
Note Holder  Issue Date  Maturity Date  Interest Rate   Default Interest Rate   Collateral  December 31, 2025   December 31, 2024 
Note #1  May 12, 2025  May 12, 2027   15.00%   15.00%  All assets  $6,999,999   $        - 
Note #2  September 25, 2025  September 25, 2026   0.00%   22.00%  Unsecured   831,600    - 
Note #3  October 8, 2025  October 8, 2026   0.00%   22.00%  Unsecured   712,800    - 
Note #4  October 7, 2025  October 7, 2026   0.00%   22.00%  Unsecured   415,800    - 
Note #5  October 15, 2025  October 15, 2026   0.00%   22.00%  Unsecured   415,800    - 
Note #6  November 17, 2025  November 17, 2026   0.00%   22.00%  Unsecured   534,600    - 
                   Gross Carrying Value   9,910,599    - 
                   Less: unamortized debt discount   (1,670,861)   - 
                   Convertible notes payable - net   8,239,738    - 
                   Short Term   3,068,878    - 
                   Long Term  $5,170,860   $- 

 

Convertible Notes Payable - Notes #1 through #6

 

Overview

 

During the year ended December 31, 2025, the Company entered into six Note Purchase Agreements with institutional investors and issued Convertible Notes (collectively, the “Notes”) with an aggregate original principal of $9,694,999. Note #1 is a senior secured obligation collateralized by a first-priority lien on substantially all of the Company’s and its subsidiaries’ assets. Notes #2 through #6 are unsecured obligations. The Notes are summarized in detail below.

 

Note #1 - Senior Secured Convertible Note

 

On May 12, 2025, the Company entered into a Senior Secured Note Purchase Agreement with an institutional investor, pursuant to which the Company issued a Senior Secured Convertible Note in the original principal amount of $6,999,999 (the “Note”), resulting in net cash proceeds of $5,405,000, after deducting $175,000 in legal fees and $420,000 in broker fees paid directly from the proceeds. The Note is secured by a first-priority lien on substantially all of the Company’s and its subsidiaries’ assets pursuant to a Security and Pledge Agreement and is fully guaranteed by certain subsidiaries of the Company.

 

In connection with the issuance, the Company repurchased 333,333 shares of its common stock from the investor at $3.00 per share. These shares were cancelled and retired and are recorded as treasury stock (see Note 9).

 

 

SURGEPAYS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2025 AND 2024

 

Interest and Amortization Terms

 

The Note accrues interest at a rate of 1.25% per month (15% per annum). Interest is payable monthly, either in cash or as payment-in-kind (“PIK Interest”) at the Company’s election. Commencing with the month ending June 30, 2026, the Note obligation amortizes in equal monthly installments of $500,000, with the remaining outstanding balance due on the Maturity Date of October 12, 2027.

 

Amendment

 

On January 31, 2026, the Company and the investor entered into an amendment to the Note, which revised the amortization commencement date from January 31, 2026 to June 30, 2026 and extended the Maturity Date from May 12, 2027 to October 12, 2027. The amendment was evaluated in accordance with ASC 470-50 and accounted for as a debt modification. Accordingly, no gain or loss was recognized, and the carrying value of the Note was not adjusted. The remaining unamortized debt discount is being amortized over the revised term to the new Maturity Date using the effective interest method. See Note 12.

 

Embedded Conversion Feature

 

The Note contains an embedded conversion option that permits the investor to convert outstanding principal and accrued interest into shares of the Company’s common stock at an initial conversion price of $4.00 per share. The Company evaluated this feature in accordance with ASC 815-10-15-74(a) and ASC 815-40. The conversion option is indexed solely to the Company’s own common stock and satisfies the fixed-for-fixed criteria under ASC 815-40-15, qualifying for the scope exception from derivative accounting. Accordingly, the Note is accounted for in its entirety as a debt instrument.

 

Warrant Issuance

 

In connection with the issuance of the Note, the Company issued warrants to purchase 700,000 shares of its common stock at an exercise price of $6.00 per share. The warrants are immediately exercisable and expire on May 12, 2030.

 

The Company allocated a portion of the proceeds to the warrants based on their relative fair value, determined using the Black-Scholes option pricing model. The fair value of the warrants at issuance was estimated at $1,084,927, which was recorded as a debt discount with a corresponding credit to additional paid-in capital.

 

 

SURGEPAYS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2025 AND 2024

 

The assumptions used in the Black-Scholes model were as follows:

 

Expected term (years)   5 
Expected volatility   105%
Expected dividends   0%
Risk free interest rate   4.09%

 

Debt Discount

 

In connection with the issuance of the Note, the Company recorded total debt discounts of $1,679,927, consisting of the following:

 

      
Fair value - warrants issued  $1,084,927 
Legal fees   175,000 
Broker fees   420,000 
Total debt discount  $1,679,927 

 

Debt discounts are being amortized to interest expense over the revised contractual term of the Note through the Maturity Date of October 12, 2027 using the effective interest method in accordance with ASC 835-30.

 

Convertible Notes Payable - Notes #2, #3, #4, #5 and #6

 

During the period from September 25, 2025 through November 17, 2025, the Company entered into five separate one-year unsecured Note Purchase Agreements with institutional investors and issued Convertible Notes (collectively, the “Notes”). In accordance with ASC 835-30, each Note was issued at a discount arising from original issue discounts, guaranteed interest capitalized at issuance, the fair value of common shares issued to investors as additional consideration, and, where applicable, debt issuance costs. On the commitment date these components are recorded as a reduction of the carrying value of the respective Notes and are amortized to interest expense using the effective interest method over each Note’s one-year contractual term.

 

These Notes had an aggregate original principal amount of $2,695,000. Guaranteed interest of $215,600 was capitalized at issuance, resulting in a total aggregate obligation of $2,910,600.

 

 

SURGEPAYS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2025 AND 2024

 

The following tables summarize the key terms and debt discount components of each issuance:

 

Convertible Notes Payable - Net
   Issue  Maturity  Original   Capitalized Guaranteed   Total   Net Cash   Total Debt 
Note Holder  Date  Date  Principal   Interest   Obligation   Proceeds   Discount 
Note #2  September 25, 2025  September 25, 2026  $770,000   $61,600   $831,600   $692,500   $224,900 
Note #3  October 8, 2025  October 8, 2026   660,000    52,800    712,800    598,000    182,720 
Note #4  October 7, 2025  October 7, 2026   385,000    30,800    415,800    348,500    106,780 
Note #5  October 15, 2025  October 15, 2026   385,000    30,800    415,800    350,000    104,580 
Note #6  November 17, 2025  November 17, 2026   495,000    39,600    534,600    448,000    126,500 
Total        $2,695,000   $215,600   $2,910,600   $2,437,000   $745,480 

 

Debt Discount Components
   Original Issue   Capitalized Guaranteed   Common Stock   Grant Date   Fair Value of Shares   Professional   Total Debt 
Note Holder  Discount   Interest   Issued   Price   Issued   Fees   Discount 
Note #2  $70,000   $61,600    30,000   $2.86   $85,800   $7,500   $224,900 
Note #3   60,000    52,800    24,000   $2.83    67,920    2,000    182,720 
Note #4   35,000    30,800    14,000   $2.82    39,480    1,500    106,780 
Note #5   35,000    30,800    14,000   $2.77    38,780    -    104,580 
Note #6   45,000    39,600    21,000   $1.90    39,900    2,000    126,500 
Total  $245,000   $215,600    103,000        $271,880   $13,000   $745,480 

 

The fair value of shares issued to investors was determined based on the quoted closing price of the Company’s common stock on each respective grant date. Total debt discounts of $745,480 are being amortized over the contractual term of each respective Note using the effective interest method in accordance with ASC 835-30.

 

Interest and Repayment Terms

 

Each Note accrues interest at 8% per annum, with a default rate of 22% per annum.

 

The guaranteed interest is capitalized at issuance and included in the total obligation.

 

 

SURGEPAYS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2025 AND 2024

 

Each Note is repayable in five equal monthly installments inclusive of the capitalized guaranteed interest, with any unpaid amounts due and payable as part of the fifth and final installment, as follows:

 

   Monthly                
Note Holder  Installment   Payment 1  Payment 2  Payment 3  Payment 4  Payment 5
Note #2  $166,320   May 25, 2026  June 25, 2026  July 25, 2026  August 25, 2026  September 25, 2026
Note #3  $142,560   May 31, 2026  June 30, 2026  July 31, 2026  August 31, 2026  October 8, 2026
Note #4  $83,160   June 7, 2026  July 7, 2026  August 7, 2026  September 7, 2026  October 7, 2026
Note #5  $83,160   June 15, 2026  July 15, 2026  August 15, 2026  September 15, 2026  October 15, 2026
Note #6  $106,920   July 17, 2026  August 17, 2026  September 17, 2026  October 17, 2026  November 17, 2026

 

Embedded Conversion Features

 

Each Note contains embedded conversion features that allow the investor to convert outstanding principal and accrued interest into shares of the Company’s common stock in three tranches:

 

First tranche (approximately 25% of the total obligation): convertible at $4.00 per share;
Second tranche (approximately 25% of the total obligation): convertible at $6.00 per share; and
Third tranche (the remaining approximately 50% of the total obligation): convertible as disclosed below.

 

Upon the earlier of i) the occurrence of an event of default or ii) the company’s failure to pay any amortization payment when due, all tranches may alternatively be converted at 85% of the lowest daily volume-weighted average price (“VWAP”) of the Company’s common stock during the five trading days immediately preceding the conversion date. All tranches are immediately exercisable at the investor’s option at their respective fixed conversion prices. The fixed conversion prices are subject to customary anti-dilution adjustments for stock splits, stock dividends, or recapitalizations. The Company may also, subject to specified price and volume conditions and with the prior written consent of the investor, effect a mandatory conversion of all or a portion of any Note into common stock.

 

Accounting Treatment

 

The Company evaluated the embedded conversion features of the Notes in accordance with ASC 815-10-15-74(a) and ASC 815-40 to determine whether bifurcation as derivative liabilities was required. The fixed-price conversion options ($4.00 and $6.00 per share) are conventional convertible features indexed solely to the Company’s own common stock that satisfy the fixed-for-fixed criteria under ASC 815-40-15 and therefore qualify for the scope exception from derivative accounting.

 

 

SURGEPAYS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2025 AND 2024

 

Each Note also contains a contingent variable conversion feature (85% of the lowest daily VWAP) that is exercisable only upon an event of default. Management has assessed the likelihood of default as remote, based on the Company’s history of compliance with its debt obligations and continued access to capital markets. Accordingly, this contingent feature does not require bifurcation, is considered clearly and closely related to the debt host under ASC 815-10-15-74(a), and qualifies for the equity scope exception under ASC 815-40. Each Note is therefore accounted for in its entirety as a debt instrument.

 

The Company reassesses the probability of default at each reporting date. Should an event of default no longer be considered remote, the contingent variable conversion feature would be bifurcated and recognized as a derivative liability at fair value, with subsequent changes in fair value recognized in earnings. As of December 31, 2025, the Company was in compliance with all terms and conditions of the Notes.

 

Notes Payable

 

The following is a summary of the Company’s Notes Payable:

 

   Note #1   Note #2   Total 
Balance - December 31, 2024  $-   $-   $- 
Proceeds from issuance of note   1,000,000    5,628,811    6,628,811 
Repayments   -    (4,751,765)   (4,751,765)
Debt discount   (48,418)   -    (48,418)
Amortization of debt discount   5,380    -    5,380 
Balance - December 31, 2025  $956,962   $877,046   $1,834,008 
                
Unamortized debt discount  $43,038   $-   $43,038 

 

The following is a detail of the Company’s Notes Payable:

 

Notes Payable - Net
Note Holder  Issue Date  Maturity Date  Interest Rate   Default Interest Rate   Collateral  December 31, 2025   December 31, 2024 
Note #1  September 9, 2025  March 9, 2026   19.00%   6.00%  Unsecured  $1,000,000   $- 
Note #2  September 9, 2025  September 9, 2026   0.00%   0.00%  Accounts receivable   877,046    - 
                   Less: unamortized debt discount   (43,038)   - 
                   Notes payable - net   1,834,008    - 
                   Short Term   1,834,008    - 
                   Long Term  $-   $- 

 

 

SURGEPAYS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2025 AND 2024

 

Note #1 - Note Issuance and Warrants

 

On September 9, 2025, the Company entered into a six-month (6) Senior Secured Note with an individual (the “Investor”), in the original principal amount of $1,000,000 (the “Note”).

 

As of December 31, 2025, the Company was in compliance with all terms and conditions of the Note.

 

Warrant Issuance and Classification

 

In connection with the issuance of the Note, the Company also issued warrants to purchase 30,000 shares of its common stock at an exercise price of $2.50/share. The warrants are immediately exercisable and remain outstanding through September 9, 2028.

 

Debt Discount

 

In connection with the issuance of the $1,000,000 note, the Company issued warrants to purchase 30,000 shares of common stock. The Company allocated a portion of the proceeds to the warrants based on their relative fair value, determined using the Black-Scholes option pricing model. The fair value of the warrants was estimated to be $48,418, which was recorded as a debt discount and is being amortized to interest expense over the term of the note. The Company also recorded a corresponding increase to additional paid-in capital of $48,418. See Note 9.

 

The fair value of the warrants was determined using the Black-Scholes model with the following assumptions:

 

Expected term (years)   3 
Expected volatility   90%
Expected dividends   0%
Risk free interest rate   3.48%

 

The debt discount will be fully amortized over the contractual term of the note (six-months).

 

Note #2 – Accounts Receivable Financing Facility and Line of Credit

 

On September 9, 2025, the Company entered into a one-year (1) Business Loan and Security Agreement (the “Agreement”) with Paragon Bank (“Paragon”) establishing a $1,500,000 accounts receivable financing facility (the “Facility”). The Facility is secured by a first-priority lien on substantially all of the Company’s accounts receivable and related collateral. The Facility is a recourse arrangement under which the Company remains liable to Paragon for all advances, including amounts related to uncollected or disputed customer receivables.

 

 

SURGEPAYS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2025 AND 2024

 

Borrowings under the Facility are available based on eligible accounts (up to 85%), subject to customary reserves and reporting requirements. The Facility is intended to provide working-capital financing and liquidity support for the Company’s operations.

 

Under the terms of the agreement, each advance is evidenced by a corresponding factoring or receivables purchase transaction recorded through the Company’s Paragon Business Manager account.

 

During 2025, Paragon purchased $5,628,811 of invoices, of which $4,751,765 had been collected and remitted by period-end. The resulting outstanding balance of $877,046 represents amounts advanced to the Company under the Facility as of December 31, 2025.

 

Paragon retains a reserve account equal to a portion of factored receivables to cover charge-backs, adjustments, and service fees (15%). At December 31, 2025, the reserve balance was $281,811, which is classified as restricted cash on the Company’s consolidated balance sheet.

 

Service charges and related finance fees of $86,481 were incurred during the year ended December 31, 2025 and are recognized as interest expense within the consolidated statements of operations

 

As of December 31, 2025, the Company was in compliance with all covenants and terms of the Facility.

 

Debt Maturities

 

The following represents the maturities of the Company’s various debt arrangements for each of the five (5) succeeding years and thereafter as follows:

 

For the Year Ended December 31,  Note Payable - Related Party   Convertible Notes Payable   Notes Payable   Notes Payable - SBA Government   Total 
                     
2026  $2,730,796   $6,410,600   $1,877,046   $11,407   $11,029,849 
2027   -    3,499,999    -    11,902    3,511,901 
2028   -    -    -    12,308    12,308 
2029   -    -    -    12,820    12,820 
2030   -    -    -    13,313    13,313 
Thereafter   -    -    -    396,584    396,584 
Total   2,730,796    9,910,599    1,877,046    458,334    14,976,775 
Less: unamortized debt discount   -    1,670,861    43,038    -    1,713,899 
Debt - net  $2,730,796   $8,239,738   $1,834,008   $458,334   $13,262,876 

 

 

SURGEPAYS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2025 AND 2024